MediGene AG has announced plans to stop early-stage research in order to focus on more advanced drug development projects. This includes continuing work on its liposome technology and finding a partner for the drug candidate, EndoTAG-1.
MediGene AG has announced plans to stop early-stage research in order to focus on more advanced drug development projects. This includes continuing work on its liposome technology and finding a partner for the drug candidate, EndoTAG-1.